% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Mamlins:1028499,
      author       = {Mamlins, Eduards and Scharbert, Lara and Cardinale, Jens
                      and Krotov, Maria and Winter, Erik and Rathke, Hendrik and
                      Strodel, Birgit and Ankrah, Alfred O. and Sathekge, Mike and
                      Haberkorn, Uwe and Kratochwil, Clemens and Giesel, Frederik
                      L.},
      title        = {{T}he {T}heranostic {O}ptimization of {PSMA}-{GCK}01 {D}oes
                      {N}ot {C}ompromise the {I}maging {C}haracteristics of
                      [99m{T}c]{T}c-{PSMA}-{GCK}01 {C}ompared to {D}edicated
                      {D}iagnostic [99m{T}c]{T}c-{EDDA}/{HYNIC}-i{PSMA} in
                      {P}rostate {C}ancer},
      journal      = {Molecular imaging $\&$ biology},
      volume       = {26},
      number       = {1},
      issn         = {1536-1632},
      address      = {Cham},
      publisher    = {Springer Nature Switzerland},
      reportid     = {FZJ-2024-04651},
      pages        = {81 - 89},
      year         = {2024},
      abstract     = {PURPOSE: Radiolabeled PSMA-ligands play a major role in
                      today's nuclear medicine. Since approval of
                      [177Lu]Lu-PSMA-617 for therapy of metastatic prostate
                      cancer, availability of 177Lu became bottleneck of supply
                      due to the high demand. Recently, a theranostic PSMA-ligand,
                      PSMA-GCK01, was developed which can be labeled either
                      diagnostically with 99mTc or therapeutically with 188Re with
                      both nuclides available from well-known generator systems.
                      This novel tracer might aid to overcome aforementioned
                      supply limitations. In this investigation, the
                      biodistribution and general imaging characteristics of
                      [99mTc]Tc-PSMA-GCK01 were compared with the diagnostic
                      reference compound [99mTc]Tc-EDDA/HYNIC-iPSMA in patients
                      with advanced stage prostate cancer. In addition, the
                      binding of both ligands to PSMA was analyzed at the
                      molecular level using molecular docking.PROCEDURES: Two
                      cohorts (n = 19 vs. n = 21) of patients with metastatic
                      castration-resistant prostate cancer matched for age, tumor
                      stage, and Gleason score underwent a planar gamma camera
                      imaging with [99mTc]Tc-EDDA/HYNIC-iPSMA or
                      [99mTc]Tc-PSMA-GCK01 prior to PSMA-ligand therapy for
                      PSMA-phenotyping. The imaging data were retrospective
                      analyzed for salivary gland, kidney, liver, soft tissue, and
                      tumor uptake on a semi-automated ROI-analysis using HERMES
                      Medical Solutions AB (HMS, Sweden).RESULTS: The data sets
                      were semi-automated quantified on a ROI-based analysis. The
                      tumor-to-background presented equal results of
                      [99mTc]Tc-PSMA-GCK01 compared to [99mTc]Tc-EDDA/HYNIC-iPSMA.
                      The physiological PSMA-positive organs like salivary gland
                      presented also equal uptake in counts/MBq (salivary gland
                      median 9.48 [99mTc]Tc-PSMA-GCK01 vs. median 9.11
                      [99mTc]Tc-EDDA/HYNIC-iPSMA), while liver-to-kidney ratio
                      presented a slight shift to the liver parenchyma using
                      [99mTc]Tc-PSMA-GCK01 (0.83) compared to
                      [99mTc]Tc-EDDA/HYNIC-iPSMA (0.55) with no statistical
                      significance. This is in agreement with the results from the
                      docking study revealing only a minor difference in the
                      docking scores for both ligands.CONCLUSIONS: The novel
                      theranostic tracer [99mTc]Tc/[188Re]Re-PSMA-GCK01
                      demonstrates comparable general imaging characteristic with
                      the reference compound [99mTc]Tc-EDDA/HYNIC-iPSMA. These
                      results pave the way for the PSMA-targeting imaging and
                      theranostic agents for a broader, rather low-cost, generator
                      applied radio-ligand therapy utilization.},
      cin          = {IBI-7},
      ddc          = {570},
      cid          = {I:(DE-Juel1)IBI-7-20200312},
      pnm          = {5241 - Molecular Information Processing in Cellular Systems
                      (POF4-524)},
      pid          = {G:(DE-HGF)POF4-5241},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {38066252},
      UT           = {WOS:001117836400001},
      doi          = {10.1007/s11307-023-01881-y},
      url          = {https://juser.fz-juelich.de/record/1028499},
}